Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | PHASE3 | RECRUITING | 830 | — | — | Apr 10, 2025 | Dec 2, 2030 | May 14, 2026 | 296 | United States, Argentina +25 |
OS is defined as the time from randomization until the date of death due to any cause.
PFS is defined as the time from randomization until radiological progression per RECIST 1.1 or death due to any cause (in the absence of progression).
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Drug: rilvegostomig |
| Arm B | ACTIVE_COMPARATOR | Drug: Pembrolizumab |
| Name | Type | Description |
|---|---|---|
| Rilvegostomig | BIOLOGICAL | Administered intravenously (IV) on Day 1 of each 21-day cycle |
| Pembrolizumab | BIOLOGICAL | Administered intravenously (IV) on Day 1 of each 21-day cycle |
Inclusion Criteria: * Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes. * Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment. * Absence of...